Jump to:
Jenny is a member of the corporate department at Ropes & Gray and advises clients on a wide range of transactions such as negotiating and structuring of strategic alliances and other collaborations, licensing transactions, co-promotion arrangements, and joint ventures.
While at Harvard Law School, Jenny served as the speakers editor for the Harvard Journal of Law & Technology and the professional development co-chair for the Harvard Asian Pacific American Law Students Association. Jenny was also a project leader for the Harvard Law Entrepreneurship Project and a research assistant to Professor Henry E. Smith for his work on the Restatement (Fourth) of Property.
Experience
IP Transactions
- Represented a biopharmaceutical company in an exclusive collaboration and license agreement with a research-based, commercial stage biopharmaceutical company.
- Represented a biopharmaceutical company in an option and license agreement with a biotechnology company.
- Represented a pharmaceutical company in a new discovery, co-development and license agreement with a specialty pharmaceutical company.
- Represented Mammoth Biosciences, Inc. in a collaboration and license agreement with Regeneron Pharmaceuticals, Inc. for research and early-stage development of novel CRISPR/Cas gene editing therapies directed to Regeneron-selected targets, and for the clinical trials and commercialization of such products.
- Represented a pharmaceutical company in negotiating option agreements with a biotechnology company focused on the discovery and development of multi-specific biologic candidates.
- Represented AbbVie in the negotiation of two collaboration and option agreements with Umoja Biopharma, under which AbbVie will obtain rights to certain products embodying Umoja's gene delivery platform, which enables the in vitro production of anti-cancer CAR-T cells.
- Represented a biotechnology company in a pair of exclusive license agreements with two universities.
- Represented Selecta Biosciences in an exclusive licensing and development agreement with Astellas Pharma.
Mergers & Acquisitions
- Represented Becton, Dickinson and Company, BD, in a definitive agreement to acquire Edwards Lifesciences' Critical Care product group, a leader in advanced hemodynamic monitoring solutions, for $4.2 billion in cash.
- Represented CIRCOR International in its $1.6 billion sale to Kohlberg Kravis Roberts & Co.
- Represented American Society of Clinical Oncology in the sale of CancerLinQ to ConcertAI.
- Represented ImmunoGen in its sale to AbbVie which will acquire ImmunoGen, and its flagship cancer therapy ELAHERE®.
Emerging Companies
- Represented Genesis Therapeutics in its $200 million round of Series B financing.